Scholarlink

Background <p>To systematically compare the efficacy and safety of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) in the treatment of resectable esophageal squamous cell carcinoma (ESCC).</p> Methods <p>Databases were searched to collect clinical studies comparing NICT and NCRT for ESCC based on propensity score analysis. Primary outcomes included overall survival (OS), disease-free survival (DFS), pathological response rate, local recurrence and distant relapse rate. Secondary outcomes included the number of lymph nodes dissected, R0 resection rate, and postoperative complication rates.</p> Results <p>11 studies involving 4,684 patients were included. The NICT group showed significantly better OS and DFS than the NCRT group (HR = 0.61, 95% CI: 0.52–0.72; HR = 0.62, 95% CI: 0.53–0.72). The pathological complete response (pCR) rate and major pathological response (MPR) rate were lower in the NICT group (RR = 0.67, 95% CI: 0.56–0.81; RR = 0.75, 95% CI: 0.65–0.86). However, there was no significant difference in the local recurrence rate between NICT and NCRT group (RR = 0.93, 95%CI 0.51–1.72, I<sup>2</sup> = 58%), and NICT group had a greater advantage in the distant relapse rate (RR = 0.51, 95%CI 0.40–0.65, I<sup>2</sup> = 0). The number of lymph nodes dissected was significantly higher in the NICT group (MD = 6.68, 95% CI: 4.00–9.36). No significant differences were observed in R0 resection rate or major postoperative complication rates between the two groups.</p> Conclusions <p>NICT demonstrated superior survival benefits compared to NCRT in the treatment of ESCC, despite its lower pCR and MPR rate. The safety of the two treatment methods were comparable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Zixian Jin,
  • Jiani Zhu,
  • Jian Zhang,
  • Jianfei Shen,
  • Bo Zhang

摘要

Background

To systematically compare the efficacy and safety of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) in the treatment of resectable esophageal squamous cell carcinoma (ESCC).

Methods

Databases were searched to collect clinical studies comparing NICT and NCRT for ESCC based on propensity score analysis. Primary outcomes included overall survival (OS), disease-free survival (DFS), pathological response rate, local recurrence and distant relapse rate. Secondary outcomes included the number of lymph nodes dissected, R0 resection rate, and postoperative complication rates.

Results

11 studies involving 4,684 patients were included. The NICT group showed significantly better OS and DFS than the NCRT group (HR = 0.61, 95% CI: 0.52–0.72; HR = 0.62, 95% CI: 0.53–0.72). The pathological complete response (pCR) rate and major pathological response (MPR) rate were lower in the NICT group (RR = 0.67, 95% CI: 0.56–0.81; RR = 0.75, 95% CI: 0.65–0.86). However, there was no significant difference in the local recurrence rate between NICT and NCRT group (RR = 0.93, 95%CI 0.51–1.72, I2 = 58%), and NICT group had a greater advantage in the distant relapse rate (RR = 0.51, 95%CI 0.40–0.65, I2 = 0). The number of lymph nodes dissected was significantly higher in the NICT group (MD = 6.68, 95% CI: 4.00–9.36). No significant differences were observed in R0 resection rate or major postoperative complication rates between the two groups.

Conclusions

NICT demonstrated superior survival benefits compared to NCRT in the treatment of ESCC, despite its lower pCR and MPR rate. The safety of the two treatment methods were comparable.